| 1.68 0.05 (3.07%) | 09-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.56  |
1-year : | 3.01 |
| Resists | First : | 2.19 |
Second : | 2.57 |
| Pivot price | 1.68 |
|||
| Supports | First : | 1.57 | Second : | 1.31 |
| MAs | MA(5) : | 1.67 | MA(20) : | 1.75 |
| MA(100) : | 4.74 |
MA(250) : | 7.63 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 11.6 |
D(3) : | 12.1 |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 20.98 | Low : | 1.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RNAZ ] has closed above bottom band by 48.1%. Bollinger Bands are 93.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.62 - 1.63 | 1.63 - 1.64 |
| Close: | 1.66 - 1.68 | 1.68 - 1.69 |
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Mon, 28 Sep 2026
Three of 14 patients had no cancer progression at one year in an experimental drug trial - Stock Titan
Wed, 23 Sep 2026
TransCode Therapeutics, Inc. (RNAZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 22 Sep 2026
A cancer treatment technology gains a Japan patent. Australia may follow. - Stock Titan
Mon, 21 Sep 2026
Transcode Therapeutics (RNAZ) interim CFO becomes reporting insider with no listed stake - Stock Titan
Thu, 10 Sep 2026
TransCode Therapeutics Announces Leadership Transition - PR Newswire
Sun, 16 Aug 2026
RNAZ Q4 2024 Earnings: $150.64 Per Share Loss Falls Short of Estimates as Pre-Revenue Losses Mount - careplusvn.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 31 (K) |
| Shares Short P.Month | 34 (K) |
| EPS | -48.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.9 % |
| Return on Equity (ttm) | -59.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -23.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|